Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Viewray (VRAY) Stock Price

News stories about Viewray (NASDAQ:VRAY) have trended somewhat positive this week, according to Accern Sentiment Analysis. The research firm rates the sentiment of media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Viewray earned a news sentiment score of 0.18 on Accern’s scale. Accern also assigned headlines about the company an impact score of 45.2411639498532 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Viewray (VRAY) opened at $9.18 on Friday. The company has a market capitalization of $617.88, a price-to-earnings ratio of -8.12 and a beta of 0.11. The company has a quick ratio of 1.20, a current ratio of 1.59 and a debt-to-equity ratio of -1.67. Viewray has a twelve month low of $3.01 and a twelve month high of $10.39.

Viewray (NASDAQ:VRAY) last posted its earnings results on Monday, November 13th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.07). The company had revenue of $12.20 million during the quarter, compared to analysts’ expectations of $18.63 million. The business’s revenue for the quarter was up 2950.0% on a year-over-year basis. equities analysts expect that Viewray will post -0.93 EPS for the current fiscal year.

Several analysts have recently issued reports on the company. BidaskClub cut Viewray from a “buy” rating to a “hold” rating in a research note on Saturday, December 9th. ValuEngine cut Viewray from a “hold” rating to a “sell” rating in a research note on Friday, September 22nd. Mizuho reissued a “buy” rating and issued a $12.00 target price on shares of Viewray in a report on Tuesday, September 26th. Finally, Northland Securities reissued a “buy” rating and issued a $10.00 target price on shares of Viewray in a report on Friday, November 17th. One analyst has rated the stock with a sell rating and six have given a buy rating to the company. Viewray has a consensus rating of “Buy” and a consensus price target of $10.60.

ILLEGAL ACTIVITY WARNING: This story was first reported by Community Financial News and is the property of of Community Financial News. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of US & international copyright legislation. The correct version of this story can be read at https://www.com-unik.info/2017/12/23/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-viewray-vray-stock-price.html.

About Viewray

ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.

Insider Buying and Selling by Quarter for Viewray (NASDAQ:VRAY)

What are top analysts saying about Viewray? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Viewray and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit